| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6299 | 2012 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 2961 | 2009 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1263 | 2022 |
| Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non–small-cell lung cancer M Cobo, D Isla, B Massuti, A Montes, JM Sanchez, M Provencio, ... Journal of clinical oncology 25 (19), 2747-2754, 2007 | 664 | 2007 |
| Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ... The Lancet Oncology 21 (11), 1413-1422, 2020 | 625 | 2020 |
| Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey of 373 patients by the International Extranodal Lymphoma Study Grfoup (IELSG). E Zucca, A Conconi, TI Mughal, AH Sarris, JF Seymour, U Vitolo, R Klasa, ... Journal of Clinical Oncology 21, 20-27, 2003 | 568 | 2003 |
| Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients R Rosell, KD Danenberg, V Alberola, G Bepler, JJ Sanchez, C Camps, ... Clinical Cancer Research 10 (4), 1318-1325, 2004 | 553 | 2004 |
| Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non–small-cell lung cancer patients with EGFR mutations R Rosell, MA Molina, C Costa, S Simonetti, A Gimenez-Capitan, ... Clinical Cancer Research 17 (5), 1160-1168, 2011 | 358 | 2011 |
| Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations JM Silva, G Dominguez, JM Garcia, R Gonzalez, MJ Villanueva, ... Cancer research 59 (13), 3251-3256, 1999 | 358 | 1999 |
| Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival J Silva, V García, A Zaballos, M Provencio, L Lombardía, L Almonacid, ... European Respiratory Journal 37 (3), 617-623, 2011 | 329 | 2011 |
| Promoter methylation of the PTEN gene is a common molecular change in breast cancer JM García, J Silva, C Peña, V Garcia, R Rodríguez, MA Cruz, B Cantos, ... Genes, Chromosomes and Cancer 41 (2), 117-124, 2004 | 309 | 2004 |
| Cancer‐associated fibroblast and M 2 macrophage markers together predict outcome in colorectal cancer patients M Herrera, A Herrera, G Domínguez, J Silva, V García, JM García, ... Cancer science 104 (4), 437-444, 2013 | 302 | 2013 |
| IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy WD Travis, S Dacic, I Wistuba, L Sholl, P Adusumilli, L Bubendorf, P Bunn, ... Journal of Thoracic Oncology 15 (5), 709-740, 2020 | 274 | 2020 |
| Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III … V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ... Journal of clinical oncology 21 (17), 3207-3213, 2003 | 271 | 2003 |
| Cancer antigen 125 associated with multiple benign and malignant pathologies C Miralles, M Orea, P Espana, M Provencio, A Sánchez, B Cantos, ... Annals of Surgical Oncology 10, 150-154, 2003 | 255 | 2003 |
| Genetic variants associated with cancer therapy–induced cardiomyopathy P Garcia-Pavia, Y Kim, MA Restrepo-Cordoba, IG Lunde, H Wakimoto, ... Circulation 140 (1), 31-41, 2019 | 247 | 2019 |
| A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth … L Paz-Ares, JM Sanchez, A Garcia-Velasco, B Massuti, G Lopez-Vivanco, ... Journal of Clinical Oncology 24 (18_suppl), 7020-7020, 2006 | 239 | 2006 |
| Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression R Rosell, L Perez-Roca, JJ Sanchez, M Cobo, T Moran, I Chaib, ... PloS one 4 (5), e5133, 2009 | 237 | 2009 |
| First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial LG Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee, L Urban, RB Caro, ... Journal of Thoracic Oncology 17 (2), 289-308, 2022 | 233 | 2022 |
| PLCG1 mutations in cutaneous T-cell lymphomas JP Vaqué, G Gómez-López, V Monsálvez, I Varela, N Martínez, C Pérez, ... Blood, The Journal of the American Society of Hematology 123 (13), 2034-2043, 2014 | 232 | 2014 |
Carlos CampsProfessor Medicine在 gva.es 的电子邮件经过验证
